Research programme: neurodegenerative diseases - Exelixis
Latest Information Update: 20 Jun 2006
At a glance
- Originator Exelixis
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 20 Jun 2006 No development reported - Preclinical for Alzheimer's disease in USA (unspecified route)
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 27 Sep 2002 Preclinical trials in Alzheimer's disease in USA (unspecified route)